WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Entry into a Material Definitive Agreement

Item1.01

On December31, 2016, WAVE Life Sciences USA, Inc. (the
Subsidiary), a wholly-owned subsidiary of WAVE Life Sciences Ltd.
(and together with the Subsidiary for purposes of this Item1.01,
the Company), exercised its option to lease additional space in
its new GMP manufacturing building, and entered into the First
Amendment (the Lease Amendment) to that certain Lease Agreement
dated as of September26, 2016, with King 115 Hartwell LLC, an
affiliate of King Street Properties Investments, LLC (the
Manufacturing Lease). For more information regarding the original
Manufacturing Lease, please refer to the Companys Form 8-K filed
with the Securities and Exchange Commission (SEC) on September27,
2016.

Under the terms of the Lease Amendment, the Company has agreed to
lease an additional 33,650 square feet to supplement the space it
leased under the Manufacturing Lease, resulting in a total of
91,211 square feet, which constitutes the entire building at 115
Hartwell Avenue, Lexington, Massachusetts (the Manufacturing
Facility). This additional square footage will support the
expansion of the Companys GMP manufacturing capabilities and
provide additional laboratory and office space. The Company has
agreed to pay an additional average base rent of approximately
$1.8 million per year for the additional space beginning on
October1, 2017. In addition, the Company is responsible for
paying certain costs and expenses, in addition to the rent,
including a proportionate share of applicable taxes, operating
expenses, and utilities.

The foregoing description of the Lease Amendment does not purport
to be complete and is qualified in its entirety by reference to
the full text of the Lease Amendment, a copy of which is attached
as Exhibit 10.1 to this Form 8-K.